Iqvia Holdings Inc.
IQVIA Inc. Completes Issuance of €950 Million Senior Notes
Summary
On June 11, 2026, IQVIA Inc., a subsidiary of IQVIA Holdings Inc., completed the issuance of €950 million in gross proceeds of 4.625% senior notes due 2033. The notes were issued under an indenture dated June 11, 2026, among IQVIA Inc., U.S. Bank Trust Company, National Association, as trustee, and certain subsidiaries of IQVIA Inc. as guarantors. The net proceeds from the notes offering will be used to refinance certain existing indebtedness and to pay fees and expenses related to the notes offering. The notes are unsecured obligations of IQVIA Inc., will mature on June 15, 2033, unless earlier repurchased or redeemed, and will bear interest at the rate of 4.625% per year, payable semi-annually on June 15 and December 15 of each year, beginning on December 15, 2026. The issuer may redeem the notes prior to their final stated maturity, subject to a customary make-whole premium, at any time prior to June 15, 2029 (subject to a customary 'equity claw' redemption right) and thereafter subject to a redemption premium declining from 2.313% to 0.000%. The indenture is filed as Exhibit 4.1 to this Current Report on Form 8-K.
Profitelligence Alerts
Get alerts for IQV
Be first to know when Iqvia Holdings Inc. files with the SEC.
Filing Categories
Advertisement
About Iqvia Holdings Inc.
Iqvia Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and contract research services. Its primary function is to support the healthcare sector by offering data-driven insights and innovations that underpin strategic decision-making across pharmaceutical, biotechnology, and medical device industries. Iqvia plays a crucial role in facilitating drug development through its comprehensive clinical research capabilities, encompassing everything from clinical trials to regulatory submissions. Additionally, its technology solutions leverage artificial intelligence and machine learning to optimize clinical and commercial operations, contributing to enhanced patient outcomes and streamlined healthcare delivery. Iqvia's integrated services impact sectors such as drug safety, patient engagement, and real-world evidence, making it an indispensable partner for healthcare companies seeking to navigate complex markets and regulatory environments. Globally recognized for its vast data repository and cutting-edge analytical platforms, Iqvia serves as a pivotal player in the transformation of the healthcare landscape, empowering organizations to accelerate innovation and improve patient care.
Official SEC Documents
Advertisement